SCHEMBL6092097

SCHEMBL6092097

COc1ccnc(NCCO)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.51
ROCK1 Q13464 2/20 0.51
TNF P01375 1/20 0.48
KDM4D Q6B0I6 1/20 0.48
CCR1 P32246 1/20 0.47
CCR5 P51681 1/20 0.47
CCR8 P51685 1/20 0.47
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RIOK2 Q9BVS4 4/20 0.46
GSK3A P49840 1/20 0.45
MAPK10 P53779 1/20 0.45
NOS3 P29474 3/20 0.44
NOS1 P29475 3/20 0.44
NOS2 P35228 3/20 0.44
HTR1A P08908 2/20 0.44
ADRA1D P25100 2/20 0.44
ADRA1A P35348 2/20 0.44
ADRA1B P35368 2/20 0.44
KARS1 Q15046 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404716 0.85 CCR1 (0.48) CCR1CCR5CCR8RIOK2GSK3A
SCHEMBL17310152 0.83 FERMT2 (0.57) CCR1CCR5CCR8RIOK2GSK3A
SCHEMBL7832301 0.82 HRH3 (0.51) CCR1CCR5CCR8RIOK2GSK3A
SCHEMBL2177165 0.81 ALDH1A1 (0.52) ROCK2ROCK1ALDH1A1SMN1; SMN2MAPK10
SCHEMBL828151 0.77 KARS1 (0.63) KDM4DALDH1A1SMN1; SMN2NOS2KARS1
SCHEMBL11465581 0.77 HSP90AA1 (0.54) ROCK2ROCK1CCR1CCR5CCR8
SCHEMBL17700550 0.77 HRH4 (0.50) ROCK2ROCK1CCR1CCR5CCR8
SCHEMBL30356806 0.75 RIOK2 (0.50) ROCK2ROCK1KDM4DALDH1A1SMN1; SMN2
SCHEMBL17310202 0.75 DYRK1A (0.49) RIOK2GSK3AMAPK10L3MBTL1
SCHEMBL25715010 0.75 NOS2 (0.46) ROCK2ROCK1TNFKDM4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060270714-A1 Novel n-substituted 2-aminopyridine derivatives ASTRAZENECA AB (SE) 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270714-A1 Novel n-substituted 2-aminopyridine derivatives NOS1, NOS2, NOS3 ROCK2 1853/4885ROCK1 1441/4885TNF 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.